

## Enzymatic quorum quenching increases antibiotic susceptibility of multidrug resistant *Pseudomonas aeruginosa*

Kiran S<sup>1</sup>, Sharma P<sup>2</sup>, Harjai K<sup>2</sup>, Capalash N<sup>1\*</sup>

<sup>1</sup>Departments of Biotechnology and <sup>2</sup>Mirobiology, Panjab University, Chandigarh.

Received: January 2011, Accepted: February 2011.

---

### ABSTRACT

**Background and Objectives:** There is increasing emergence of multidrug resistant *Pseudomonas aeruginosa* (MDRPA) strains and drug resistance is positively-correlated with biofilm-forming ability. Since about 10% of *P. aeruginosa* genome is controlled by quorum sensing (QS), alteration in its antibiotic susceptibility by targeting QS was the focus of the present study.

**Materials and Methods:** One day biofilms of PAO1 and three urinary tract infection MDRPA isolates (PA2, PA8 and PA18) were formed in 96-well microtiter plate. Biofilms were exposed to concentration gradient of ciprofloxacin and gentamicin to obtain Minimum Biofilm Eradication Concentration (MBEC) by direct enumeration method. Susceptibility of 24 h biofilms was evaluated by treatment with ciprofloxacin and gentamicin *per se* and in combination with lactonase. The effect was also examined on 72 h biofilms by Scanning Electron Microscopy.

**Results:** Lactonase treatment did not have any effect on growth of the selected strains but 73.42, 69.1, 77.34 and 72.5% reduction of biofilm was observed after lactonase (1 unit) treatment, respectively. Antibiotics in combination with lactonase (0.3 units) resulted in an increased susceptibility of the biofilm forms by > 3.3, 4, 5 and 1.5 folds of MBEC, for ciprofloxacin and > 6.67, 12.5, 6 and > 2.5 folds, for gentamicin respectively, which could be due to the disruption of biofilm by lactonase treatment as shown by scanning electron microscopy. Also there was significant reduction ( $p < 0.001$ ) in virulence factor production by the strains.

**Conclusion:** Lactonase treatment increased antibiotic susceptibility of the biofilms of MDRPA isolates underscoring the potential of quorum quenching in antimicrobial therapeutics.

**Keywords:** Multidrug resistance, *Pseudomonas aeruginosa*, AHL Lactonase, Biofilm, Antibiotic Susceptibility, antimicrobial therapeutics

---

### INTRODUCTION

*Pseudomonas aeruginosa* is a leading opportunistic nosocomial pathogen associated with significant morbidity and mortality due to cystic fibrosis, bacteremia, endocarditis, osteomyelitis including cranial nerve palsies, gastrointestinal upsets, burns, and ventilator-associated pneumonia among intubated patients (1-4).

This organism is problematic because of impressive genetically encoded mechanisms of intrinsic resistance and the potential to mutate and gain resistance to current antibiotics (5) which primarily corresponds its biofilm forming ability (1). Most notably, fluoroquinolones influence emergence of multidrug resistant strains (6-8). Aminoglycosides also have been documented ineffective even in combination with other antibiotics due to newly evolving resistant strains (9-12). Therefore, ciprofloxacin (fluoroquinolone) and gentamicin (aminoglycoside) have been selected for investigation in the present study.

With the wide application of *in vivo* artificial devices such as contact lens, synthetic valves and artificial joints, *P. aeruginosa* gain access into the body and form

---

\* Corresponding author: Dr. Neena Capalash  
Address: Department of Biotechnology, Panjab University,  
Chandigarh 160014, India.  
Tel: +91-172-2534091  
Fax: +91-172-2541409  
E-mail: d\_susiin@yahoo.com

**Table 1.** Characteristics of bacterial strains/plasmids.

Bacterial strains	Relevant characteristics/ genotype	Growth conditions	Reference
<i>Agrobacterium tumefaciens</i> NT1(pDCI41E33) (Indicator strain)	<i>traG</i> : <i>lacZ traR</i> in pDSK519; Km <sup>r</sup> autoinducer reporter plasmid	Kanamycin (50 µg/ml) at 30°C, AB medium	(15)
<i>E. coli</i> DH5α	<i>deoR, endA1 gyrA96, hsdR17(rK<sup>-</sup> mK<sup>+</sup>), recA1, relA1, supE44, thi-1, Δ(lacZYA- argFV169), Ø80lacZΔM15, F<sup>-</sup></i>	LB medium, 37°C	(16)
<ul style="list-style-type: none"> <li>• <i>P. aeruginosa</i> PAO1</li> <li>• PA2,PA8,PA11,PA18, G1,G9,G10 and G13</li> <li>• 2663, 3633, 3751, 3849, 3878, 3882, 4250, 4287, 4299 and 4303.</li> </ul>	Wild type strain Clinical urinary tract infection isolates Clinical isolates from sepsis patients	LB medium, 37°C	(17) This study
<b>Plasmids used</b>			
pMAL-t- <i>aiiA</i>	Expression vector containing lactonase gene ( <i>aiiA</i> ) from <i>Bacillus thuringiensis</i> 4A3		(18)

biofilm. The established biofilms provides permeability barrier for antibiotics (13), making the treatment of *P. aeruginosa* infections intractable. Quorum sensing (QS) is known to play a pivotal role in the virulence of *P. aeruginosa* (5). Its QS system is composed of the LasR/I and the RhIR/I signal systems, which produce two typical autoinducers: N-(3-oxo-dodecanoyl)-L-homoserine lactone (OdDHL) and N-butyryl-L-homoserine lactone (BHL), respectively. DNA chip analysis has indicated that *P. aeruginosa* genome has over 300 genes under the control of QS system, including genes related to important virulence factors and biofilm formation (14) but there are equivocal reports about antibiotic resistance being regulated by QS.

The aim of the current study was to test the hypothesis that targeting the dissemination of QS molecules by enzymatic degradation may affect antibiotic susceptibility of *P. aeruginosa* strains.

## MATERIALS AND METHODS

**Strains, media and plasmids.** All bacterial strains and plasmids used in this work along with growth conditions are listed in Table 1. Eight urinary tract infection (UTI) and ten sepsis isolates of *Pseudomonas aeruginosa* isolated from clinical specimens in hospital diagnostic laboratories were subjected to preliminary confirmatory tests using Difco™ *Pseudomonas* Isolation Agar followed by Kligler Iron Agar and Kovac's oxidase test. The strains were maintained in Luria Bertani (LB) medium, but 2% peptone was used for virulence assays.

**Selection of clinical isolates of *P. aeruginosa*.** For biofilm forming ability, *P. aeruginosa* (10<sup>6</sup> cfu/ml)

was seeded into wells of 96-well microtiter plate containing 100µl sterile LB. Un-inoculated LB was taken as control (CW). The plate was incubated at 37°C for 24 h and growth (G) was determined spectrophotometrically at OD<sub>600nm</sub>. Wells were vigorously washed four times with PBS (pH 7.2), crystal violet (1%) was added and the plate was incubated for 10 min. Again the wells were washed and dried thoroughly. 95% ethanol was added to each well and was kept for 10-15 min. The solution from each well was pipetted to fresh wells, biofilm formation (AB) was measured spectrophotometrically at OD<sub>575nm</sub> and specific biofilm forming index (SBF) was calculated using the formula  $AB-CW/G$ . The degree of biofilm production was classified in three categories: weak (SBF ≤ 0.5), moderate (0.5 > SBF ≤ 1), and strong (SBF > 1) (19).

MDRPA isolates were screened for lactone production by AHL plate bioassay using *A. tumefaciens* NT1 indicator strain. Briefly, lactones were extracted from overnight cultures with acidified ethyl acetate using 0.01% glacial acetate (2) and were concentrated 1000 times. AB agar plate was overlaid with AB medium containing 0.5% mannitol, X-gal (40 µg/ml), 10% inoculum of *A. tumefaciens* NT1 (pDCI41E33) reporter strain (OD<sub>600nm</sub> 1.8), 50 µg/ml kanamycin and 0.75% agar. Wells were punched aseptically and the extracted lactones were loaded. Plates were incubated for 24-48 h and presence of lactone was indicated by blue zones around the wells (15).

Kirby-Bauer disc diffusion method was used following NCCLS guidelines for the selection of MDRPA isolates (resistant to ≥ 3 different classes of antibiotics) (20). Different antibiotics used were

aminoglycosides [amikacin (30 µg), gentamicin (10 µg), kanamycin (10 µg), streptomycin (10 µg), tobramycin (10 µg)], fluoroquinolone [ciprofloxacin (5 µg)], β-lactams [ampicillin (10 µg)] and polyketide [tetracycline (10 µg)].

**Heterologous expression of *aiiA* in *E. coli* DH5α and lactonase preparation.** Lactonase gene (*aiiA*) fused to maltose binding protein (MBP) was cloned in expression vector pMAL-c2x (gift from Dr. Walter Fast, University of Texas, Austin) and *E. coli* DH5α (12.5 kV/cm, 200 Ω) transformants were selected on ampicillin (50 µg/ml) LB agar plates (16). Expression and production of lactonase was done by method of Thomas et al. (18).

**Lactonase activity.** Lactonase activity was calculated as substrate (µM) degraded/min/µg of lactonase. Residual lactone extracted after incubation of 3-oxo-C<sub>12</sub> HSL (Fluka, USA) and lactonase at 37°C for 5, 10 and 15 min was added to 96 well plate containing 100 µl of 1:10 diluted overnight grown culture of *A. tumefaciens* NT1 in AB medium supplemented with 0.5% mannitol, 50µg/ml kanamycin and 40 µg/ml X-gal (15) and incubated for 24 h at 37°C. OD was taken at 490 nm (21) and residual lactone was estimated from the standard curve of 3-oxo-C<sub>12</sub>-HSL (0.01 µM-10 µM).

**Biofilm assay.** A static biofilm assay was performed with selected MDR strains of *P. aeruginosa* in 96 well polystyrene microtiter plates. 24 h biofilm was treated in the absence (control) and presence of lactonase gradient (0-1 Unit). After 6 h of treatment at 37°C, excess broth was removed and used to enumerate planktonic growth on LB agar, and the wells were washed four times with sterile PBS. 150µl of PBS was added to all the wells and the microtiter plate with lid was placed in chilled water bath. Sonicator tip was dipped in water-bath and sonicated for 10 sec at 40% power to loosen the biofilm and bacterial cells in biofilms (cfu/ml) were enumerated on LB agar.


**Effect of lactonase on antibiotic resistance of clinical isolates of *P. aeruginosa*.** Minimum biofilm eradication concentration (MBEC) of gentamicin and ciprofloxacin was estimated on 24 h biofilms formed by the selected *P. aeruginosa* strains by giving treatment at 0-5 mg/ml and 0-3 mg/ml, respectively.

Concentration of antibiotic at which no viable cell-counts in biofilms were obtained was taken as MBEC. To study the effect of lactonase on antibiotic susceptibility of the selected *P. aeruginosa* isolates, antibiotic treatment was given in absence (control) and presence of lactonase (0.3 Units) for 6 h at 37°C followed by viable counting of biofilm forms as explained above.

**Microscopic analysis.** Scanning electron microscopic analysis of the effect of lactonase and gentamicin and the effect of both in combination on PAO1 biofilm was performed. For biofilm formation, cell-suspension (10<sup>6</sup> cfu/ml) from overnight grown culture at 37°C, 180 rpm was made in AB medium supplemented with 0.3 mM glucose and was used to form 24 and 72 h biofilm on cover-slips [in four sets: untreated control, lactonase (0.3 units) and antibiotic treatment *per se* and in combination] (22). Then the respective treatment for 8 h at 37°C was given to the established biofilm. Cover-slips were vigorously washed 8-10 times with sterile PBS (pH 7.2, 50 mM) and fixed with 2.5% glutaraldehyde for 3 h. The samples were dehydrated using ethanol gradient, for 15 min each. The samples were mounted onto aluminum stubs, sputter-coated with gold-palladium (1.8 kV and 6 mA for 60 s) and desiccated. The electron micrographs were analyzed by digital scanning electron microscope JSM 6100 (JEOL).

**Effect of lactonase on the production of virulence factors of *P. aeruginosa*.** Selected strains of *P. aeruginosa* were grown in 2% bactopectone in presence and absence (control) of lactonase (0.3 Unit) in triplicates. After 16 h incubation at 37°C, 180 rpm; the cell density was recorded at OD<sub>600nm</sub> and cell free supernatant (CFS) was obtained by centrifugation at 12,000 g for 15 min, 4°C for the estimation of virulence factors.

Pyochelin was estimated in 1.0 ml of CFS by adding 1 ml each of 0.5 N HCl, nitrite molybdate reagent and 1 N NaOH. Final volume was made to 5 ml with distilled water and the absorbance was read at 510 nm (23). Protease activity was checked on 0.1 ml of azocasein (10 mg/ml) dissolved in 50 mM PBS (pH 7.5) (Sigma, USA) at 37°C for 1 h. Yellow colored (azo group) hydrolyzed end-product was spectrophotometrically recorded at 405 nm after centrifugation (12,000 g, 2 min) and results were expressed as OD<sub>405</sub> nm/h growth unit (24).



**Fig. 1.** Specific biofilm forming index of *P. aeruginosa* PAO1 strain and clinical isolates  $\pm$  standard deviations.

Elastolytic activity was measured on elastin–congo red (ECR). Optical density was taken at 490 nm and elastase activity was expressed as absorbance at 490 nm/mg of ECR/h (25). For pyocyanin estimation, pyocyanin was extracted from CFS with 5:1 v/v of chloroform. The chloroform phase was removed and extracted with 0.2 N HCl. Absorbance was taken at 490 nm. Rhamnolipid production was estimated in 1.0 ml CFS by adding 1N H<sub>2</sub>SO<sub>4</sub>. Absorbance was taken at 490 nm (26).

Results were statistically analyzed by applying the student's t-test for calculating p- values.

## RESULTS

All clinical isolates were observed to be Gram-negative motile rods. Although all the isolates showed growth on Pseudomonas isolation agar, only PAO1, PA2, PA8, PA11 and PA18 produced pyocyanin after 18 h, however, other isolates produced pyocyanin pigment after 48 h of incubation at 37°C. On KIA medium, no acid production in slant and butt indicated that the isolates fermented neither dextrose nor lactose. Also, all the strains were observed to be oxidase positive; therefore, all the *P. aeruginosa* clinical isolates and PAO1 wild-type strain was

subjected to screening for biofilm formation, lactone production and antibiotic resistance.

### Selection of clinical isolates of *P. aeruginosa*.

All the clinical isolates were observed to produce lactones, however, the production was higher among UTI isolates as indicated by the intensity of blue zones around the wells (data not shown) but wide variation in biofilm forming abilities was observed (Fig. 1). PAO1 along with PA2, PA8 and PA18 UTI isolates exhibited the strong biofilm forming ability (SBF > 1); PA11, G1, G9, G10 and G13 UTI isolates had the moderate (SBF > 0.5) and all the sepsis isolates showed the weak biofilm forming ability (SBF  $\leq$  0.5).

The results of antibiotic disc diffusion assay showed multi-drug resistance among three urinary tract infection (UTI) strains (PA2, PA8, and PA18) and six sepsis isolates (2635, 3633, 3751, 3882, 4299 and 4303) (Fig 2A). PAO1, PA2, PA8, PA18, 3633 and 4299 showed 100% antibiotic resistance against the set of antibiotics used. Beside wide variation in antibiotic resistance levels of the isolates, the whole spectrum of commonly administered antibiotics also showed variable (53-95%) and high percentage (> 50%) of strain resistance (Fig. 2B). Majority of the strains (95%) showed resistance to ampicillin followed by aminoglycosides (71%). Among aminoglycosides, frequency of resistance to antibiotics followed the order: kanamycin (90%) > streptomycin and amikacin (74%) > tobramycin (63%) > gentamicin (53%). 58% strains were resistant to ciprofloxacin and 53% against tetracycline (Fig. 2B).

Since PAO1, PA2, PA8 and PA18 strains exhibited strong lactone production; biofilm formation and antibiotic resistance, these were selected for the further investigation. Also, the AHL molecules produced by these selected *P. aeruginosa* strains were observed to be completely degraded by AiiA lactonase (Fig. 3).

### Effect of lactonase on biofilm formation.

Lactonase (1 unit) treatment significantly ( $p < 0.01$ ) reduced biofilm formation by 73.5, 68.8, 76.8 and 70.7% in PAO1, PA2, PA8 and PA18 strains, respectively (Table 2a) and the effect was found to be concentration dependent. There was an increase in the planktonic cell count in the medium surrounding the treated biofilm (Table 2b) which increased with the increase in lactonase concentration (0-1 units). The highest transformation of biofilm forms to planktonic forms (71.2%) due to lactonase (1Unit) treatment was

**Table 2a** . Effect of lactonase on biofilm formation of *P. aeruginosa* isolates

Lactonase (Units)	% reduction in log <sub>10</sub> cfu/ml counts of biofilm after lactonase treatment ± SD			
	PAO1	PA2	PA8	PA18
0	0 ± 0.065	0 ± 0.97	0 ± 0.47	0 ± 0.17
0.05	2.7 ± 1.01	4.16 ± 0.74	4.59 ± 0.92	7.73 ± 1.3
0.1	25.7 ± 0.17	9.36 ± 0.14	13.8 ± 0.61	24.79 ± 0.8
0.2	38.87 ± 0.27	21.6 ± 0.63	23.55 ± 0.84	34.1 ± 0.62
0.3	49.84 ± 0.09	52.27 ± 0.62	46.6 ± 0.16	47 ± 0.51
0.4	51.25 ± 0.18	53.62 ± 0.81	48.9 ± 0.71	49.3 ± 0.93
0.5	56.52 ± 0.65	56.38 ± 1.09	51.08 ± 0.64	52.99 ± 0.65
0.6	58.24 ± 0.09	57.51 ± 0.72	53.34 ± 0.53	54.67 ± 0.42
0.7	61.53 ± 0.29	58.266 ± 0.65	55.11 ± 0.19	57.96 ± 0.84
0.8	65.12 ± 0.83	63.03 ± 0.82	66.95 ± 0.71	61.97 ± 0.91
0.9	68.14 ± 1.56	69.2 ± 0.37	71.13 ± 0.19	70.32 ± 0.21
1.0	73.42 ± 0.79	69.1 ± 0.61	77.34 ± 0.92	72.5 ± 0.19

observed for PA2 strain and the least was observed for PAO1 strain of *P. aeruginosa* (63.42%) (Table 2b).

**Effect of lactonase on Minimum Bactericidal Eradication Concentration.** 24 h biofilms of selected MDR strains of *P. aeruginosa* showed different levels of reduction in MBECs (Fig. 3a-3d) against ciprofloxacin and gentamicin when treated in the presence of 0.3 units of lactonase. MBECs of both ciprofloxacin and gentamicin could not be achieved even at 5000 µg/ml, in case of PAO1 strain but with lactonase treatment, MBEC for both the antibiotics was achieved at 1500 µg/ml and 750 µg/ml, respectively (Fig. 4a). Lactonase treatment thus potentiates the antibiotic efficiency because biofilm eradication could be achieved at sub-MBEC levels for both gentamicin and ciprofloxacin.

MBEC of ciprofloxacin and gentamicin against MDR PA2 isolate of *P. aeruginosa* was 2000 and 4000 µg/ml, respectively, which reduced to 500 µg/ml and 300 µg/ml in presence of lactonase resulting


in 4 and 12.5 folds reduction in MBECs, respectively (Fig. 4b).

Gentamicin showed higher MBEC against all the four strains of *P. aeruginosa*. For PA8 strain, MBEC for ciprofloxacin and gentamicin was 2000 µg/ml and 5000 µg/ml, which is approximately 100 times the permissible dosage prescribed for human subjects. Lactonase treatment reduced the MBEC values by 5 and 6 folds, respectively (Fig. 4c). PA18 strain also showed high resistance against both ciprofloxacin (4000 µg/ml) and gentamicin (> 5000 µg/ml), however, lactonase treatment resulted in reduction of MBEC levels by 1.5 and > 2.5 folds, respectively (Fig. 4d).


Microscopic examination of electron micrographs showed multiple cells in contact with one another and irreversibly attached to substratum, with no pili i.e. motility was ceased in attached cells (Fig. 5a) in 24 h biofilm of PA2 isolate. At some fields, cell-clusters had initiated progressive layering. Mushroom and pillar-like structures were visualized in 72 h biofilm

**Table 2b.** Effect of lactonase on a) biofilm formation; b) planktonic forms of *P. aeruginosa* PAO1 strain and three UTI clinical isolates.

Units of lactonase	% increase in log <sub>10</sub> cfu/ml counts of planktonic cells after lactonase treatment ± SD			
	PAO1	PA2	PA8	PA18
0	0 ± 0.065	0 ± 0.065	0 ± 0.065	0 ± 0.065
0.2	8.87 ± 0.17	10.1 ± 0.29	5.8 ± 1.27	9.87 ± 0.79
0.4	20.25 ± 1.18	25.2 ± 0.28	19.26 ± 0.18	25.25 ± 0.48
0.6	38.24 ± 1.09	42.14 ± 0.39	28.27 ± 0.09	36.24 ± 0.49
0.8	45.12 ± 0.73	55.16 ± 0.3	35.32 ± 0.83	42.12 ± 1.13
1	63.42 ± 0.29	71.2 ± 0.7	69.41 ± 0.79	65.42 ± 0.13




**Fig. 2A.** Percent antibiotic resistance by different *P. aeruginosa* strains: 1) PAO1, 2) PA2, 3) PA8, 4) PA11, 5) PA18, 6) G1, 7) G9, 8) G10, 9) G13, 10) 2663, 11) 3633, 12) 3751, 13) 3849, 14) 3878, 15) 3882, 16) 4250, 17) 4287, 18) 4299, 19) 4303. **Fig. 2B.** Percent strain resistance to different antibiotics.




1. PAO1 lactones treated with AiiA lactonase
2. PAO1 lactones
3. PA8 strain lactones treated with AiiA lactonase
4. PA 8 strain lactones
5. PA18 strain lactones treated with AiiA lactonase
6. PA18 strain lactones
7. PA2 strain lactones treated with AiiA lactonase
8. PA2 strain lactones

**Fig. 3.** Effect of lactonase on lactones produced by *P. aeruginosa* PAO1 strain and three UTI clinical isolates.




**Figs. 4a-d.** Effect of lactonase treatment on antibiotic resistance of *P. aeruginosa* strains a) PAO1 wild-type b) PA2 c) PA8 d) PA18.



**Fig. 5 (a-f).** SEM of biofilm formed by PA2 isolate of *P. aeruginosa* on glass surface using Scanning Electron Microscope (Model JSM6100-JEOL). Fig. a) 24 h biofilm; b, c) 72 h biofilm; d) gentamicin (100 µg/ml) treated 72 h biofilm; e) lactonase (0.3 units) treated 72 h biofilm; f) gentamicin (100 µg/ml) and lactonase (0.3 units) treated 72 h biofilm





**Fig. 6.** Effect of lactonase on virulence factors of *P. aeruginosa* PAO1 strain and three selected UTI clinical isolates (PA2, PA8 and PA18.)

(Fig. 5b, 5c) which persisted in gentamicin (sub-MBEC) treated 72 h biofilm but it resulted in altered cell morphology i.e. the cells turned spherical (Fig. 5d). Clustering and mushroom-like structures were absent when treatment was given with lactonase *per se* and in combination with gentamicin, respectively (Fig. 5e, 5f).

Also, there was a significant decrease ( $p < 0.001$ ) in the virulence factors after lactonase (0.3 U) treatment. Pyocyanin was reduced in range of 85-93%, protease activity by 86-95%, elastase activity by 69-91% and pyochelin secretion by 40-90% along with rhamnolipids production in the range of 67-94% in different MDR strains of *P. aeruginosa* (Fig. 6).

## DISCUSSION

Intriguing successful reports of QS inhibitors like quorum quenching (QQ) enzymes and synthetic chemicals in controlling virulence have underscored the validity of QQ strategy against numerous human and plant pathogens. There is very little data on its application in combating drug resistance. With the widespread use of extended-spectrum antibiotics, clinical evolution of MDRPA strains is rising (27-

30) which contributes to the persistence of biofilm infections that necessitates early multidisciplinary control interventions.

To analyze the effect of lactonase on antibiotic susceptibility of clinical isolates of *P. aeruginosa*, the sampling was focused on UTI and sepsis isolates because high rates of mortality (70%) are due to UTI, burn wounds, sepsis and resultant endocarditis (3, 4). The clinical isolates were assayed for lactone production, biofilm formation and multidrug resistance prior to selection for further analytical studies because clinical isolates could be QS mutants which do not produce AHL auto-inducers and have reduced expression of virulence traits (31). During selection, it was observed that UTI isolates were strong biofilm and lactone producers *vis-à-vis* sepsis isolates. This striking feature couldn't be explained because both adherent and invasive forms i.e. UTI and sepsis forms, respectively, are strong biofilm formers (19). Also there is no comparative analysis yet reported for the variable physiological responses by isolates from different body sites. But the higher lactone production and SBF index of UTI isolates could provide no advantage in multidrug resistance as only three UTI (PA2, PA8 and PA18) and six sepsis isolates (2635, 3633, 3751, 3882, 4299 and 4303) were MDRs along with PAO1 strain. Since, PAO1, PA2, PA8 and PA18 fulfilled all the selection parameters of antibiotic resistance, biofilm and lactone production, these were selected for further investigations.

In an experiment on lactonase effect on biofilms, lactonase was observed to eradicate 24 h biofilms in concentration dependent manner and was independent of the biofilm species. Since biofilms are 100-1,000 times recalcitrant to antibiotics than their planktonic counterparts (2) and reach an accumulation plateau by 24 h (32-34), antibiotic susceptibility in this work was investigated on 24 h biofilms. Although all the biofilms exhibited higher but variable resistance to gentamicin *vis-à-vis* ciprofloxacin but lactonase treated biofilms exhibited enhanced susceptibility to both the antibiotics irrespective of the biofilm species. The higher resistance to gentamicin could be because of delayed transportation of gentamicin across the *P. aeruginosa* biofilm due to more and tighter binding sites (35, 36) which reduces gentamicin activity due to enzymatic degradation during the course of penetration. Also, *P. aeruginosa* biofilms have been reported to display higher resistance to gentamicin *vis-à-vis* *E. coli* and *Klebsiella* biofilms (36). Although

the role of quorum sensing in antimicrobial resistance is not yet clear, this work resolves the role of quorum sensing in antibiotic resistance of *P. aeruginosa* and is confluent with the few of previous studies showing antibiotic resistance due to QS regulated SdiA protein in *E. coli* (37), QS-multi-drug efflux symports in *P. aeruginosa* (38), and AI-2 QS system in *Streptococcus anginosus* (39) but contrary to that of Butler et al. (40) who stated that resistance is directly correlated with density of cells. For further analysis, microscopical examination was performed.

Electron micrographs showed ample microcolonies and typical mushroom and pillar-like structures in 24 h and 72 h biofilm, respectively. The microscopic examination of untreated and gentamicin treated 72 h biofilm showed similar density of bacterial cells but gentamicin treatment caused marked morphological alterations accompanied by rounding of cells. Such morphological alterations of bacterial cells could be due to impairment in synthesis of certain enzymes involved in cell-wall formation as aminoglycosides don't influence the cell wall composition directly (41, 42). Also 72 h biofilm treated with lactonase *per se* and in combination with gentamicin showed abundant scattered cells with rounded cells in the latter. It showed that lactonase enzyme had the significant role in biofilm eradication *vis-à-vis* gentamicin because number of scattered cells was similar in both the samples. These results underscores the potential of lactonase in eradicating the established mature biofilms as compared to previous works that showed efficiency of QS inhibitors, lactonase and acylase enzymes in inhibiting biofilm formation when were allowed to act during inception (32, 43, 44). Thus, manipulating QS pathway of bacterial pathogens may provide an important approach in control of biofilm-associated virulence and development of new anti-bacterial therapeutics.

Furthermore, lactonase treatment significantly reduced ( $p < 0.001$ ) the production of pyocyanin, pyochelin, protease and elastolytic activity which are controlled by *las* QS system and rhamnolipids production by *rhl* QS system (17). Thus, AiiA lactonase quenches all the major lactones (C<sub>4</sub>-HSL by *rhl* system alongwith 3-oxo-C<sub>12</sub>-HSLs by *las*) produced by *P. aeruginosa* strains that regulate virulence factor expression.

The present study shows promising potential of enzymatic quorum quenching to combat not only the virulence but also uprooting the multidrug resistance

menace due to emerging antibiotic resistant *P. aeruginosa* strains. Thus, this area deserves further investigation for application of lactonase in alternate antimicrobial therapy (45-49).

## ACKNOWLEDGMENTS

The first author acknowledges University Grant Commission (UGC), New Delhi; for providing the research fellowship. The authors wish to thank Dr. Walter Fast, University of Texas, College of Pharmacy (Austin, Texas) for providing pMAL-t-*aiaA* plasmid containing the lactonase gene.

## REFERENCES

1. Fricks-Lima J, Hendrickson CM, Allgaier M, Zhuo H, Wiener-Kronish JP, et al. Differences in biofilm formation and antimicrobial resistance of *Pseudomonas aeruginosa* isolated from airways of mechanically ventilated patients and cystic fibrosis patients. *Int J Antimicrob Agents* 2011; 37: 309-315.
2. O'Toole GA. Microtiter dish biofilm formation assay. *J Vis Exp* 2011; 47: 2437.
3. Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant *Pseudomonas aeruginosa*. *Clin Microbiol Infect* 2005; 11 17-32.
4. Zhuo H, Yang K, Lynch SV, Dotsen RH, Glidden DV, Singh G, et al. Increased mortality of ventilated patients with endotracheal *Pseudomonas aeruginosa* without clinical signs of infection. *Crit Care Med* 2008; 36: 2495-2503.
5. Dotsch A, Becker T, Pommerenke C, Magnowska Z, et al. Genomewide identification of genetic determinants of antimicrobial drug resistance in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2009; 53: 2522-2531.
6. Montero M, Domínguez M, Orozco-Levi M, Salvadó M, Knobel H. Mortality of COPD patients infected with multi-resistant *Pseudomonas aeruginosa*: a case and control study. *Infection* 2009; 37: 16-19.
7. Pena C, Suarez C, Tubau F, Dominguez A, Sora M, Pujol M, et al. Carbapenem-resistant *Pseudomonas aeruginosa*: factors influencing multidrug-resistant acquisition in non-critically ill patients. *Eur J Clin Microbiol Infect Dis* 2009; 28: 519-522.
8. Chang KC, Yew WW, Chan RC. Rapid assays for fluoroquinolone resistance in *Mycobacterium tuberculosis*: a systematic review and meta-analysis. *J Antimicrob Chemother* 2010; 65: 1551-1561.
9. Hassan A, Usman J, Kaleem F, Khan A, Hussain Z. *In vitro* activity of aminoglycosides,  $\beta$  lactam- $\beta$  lactamases inhibitor combinations and tetracyclines against multi-drug resistant *Acinetobacter baumannii*, isolated from a tertiary care hospital. *J Microbiol Antimicrob* 2010; 2: 47-50.

10. Davis MA, Baker KN, Orfe LH, Shah DH, Besser TE, Call DR. Discovery of a gene conferring multiple-aminoglycoside resistance in *Escherichia coli*. *Antimicrob Agents Chemother* 2010; 54: 2666-2669.
11. Macmaster R, Zelinskaya N, Savic M, Rankin CR, Conn GL. Structural insights into the function of aminoglycoside-resistance A1408 16S rRNA methyltransferases from antibiotic-producing and human pathogenic bacteria. *Nucleic Acids Res* 2010; 38: 7791-7799.
12. Endimiani A, Hujer KM, Hujer AM, Armstrong ES, Choudhary Y, et al. ACHN-490, a neoglycoside with potent *in vitro* activity against multidrug-resistant *Klebsiella pneumoniae* isolates. *Antimicrob Agents Chemother* 2009; 53: 4504-4507.
13. Diggle SP, Crusz SA, Camara M. Quorum sensing. *Curr Biol* 2007; 17: R907-910.
14. Kohler T, Perron GG, Buckling A, van Delden C. Quorum sensing inhibition selects for virulence and cooperation in *Pseudomonas aeruginosa*. *PLoS Pathog* 2010; 6: e1000883.
15. Shaw PD, Ping G, Daly SL, Cha C, Cronan JE, Rinehart K, et al. Detecting and characterizing N-acyl-homoserine lactone signal molecules by thin-layer chromatography. *Proc Natl Acad Sci (USA)* 1997; 94: 6036-6041.
16. Sambrook J, Russell DW (2001). Molecular cloning: a laboratory manual. 3rd ed. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, NY.
17. Reimann C, Ginet N, Michel L, Keel C, Michaux P, Krishnapillai V, et al. Genetically programmed autoinducer destruction reduces virulence gene expression and swarming motility in *Pseudomonas aeruginosa* PAO1. *Microbiology* 2002; 148: 923-932.
18. Thomas PW, Stone EM, Costello AL, Tierney DL, Fast W. The quorum-quenching lactonase from *Bacillus thuringiensis* is a metalloprotein. *Biochemistry* 2005; 44: 7559-7569.
19. Martinez-Medina M, Naves P, Blanco J, Aldeguez X, Blanco JE, et al. Biofilm formation as a novel phenotypic feature of adherent-invasive *Escherichia coli* (AIEC). *BMC Microbiol* 2009; 9: 202-217.
20. Wouafo M, Nzouankeu A, Kinack JA, Fonkoua MC, Ejenguele G, et al. Prevalence and antimicrobial resistance of *Salmonella* serotypes in chickens from retail markets in Yaounde (Cameroon). *Microb Drug Resist* 2010; 16: 171-176.
21. Engler KH, Coker RD, Evans IH. A colorimetric technique for detecting trichothecenes and assessing relative potencies. *Appl Environ Microbiol* 1999; 65: 1854-1857.
22. Deligianni E, Pattison S, Berran D, Ternan NG, Haylock RW, et al. *Pseudomonas aeruginosa* cystic fibrosis isolates of similar RAPD genotype exhibit diversity in biofilm forming ability *in vitro*. *BMC Microbiol* 2010; 10: 38.
23. Yadav V, Harjai K, Kaur R, Joshi K, Sharma S. Urovirulence of *Pseudomonas aeruginosa*: planktonic vs. biofilm cells. *Folia Microbiologica* 2004; 49: 465-470.
24. Chessa JP, Petrescu I, Bentahir M, Van Beeumen J, Gerday C. Purification, physico-chemical characterization and sequence of a heat labile alkaline metalloprotease isolated from a psychrophilic *Pseudomonas* species. *Biochim Biophys Acta* 2000; 1479: 265-274.
25. Visca P, Chiarini F, Mansi A, Vetriani C, Serino L, Orsi N. Virulence determinants in *Pseudomonas aeruginosa* strains from urinary tract infections. *Epidem Infect* 1992; 108: 323-336.
26. Abdel-Mawgoud AM, Aboulwafa MM, Hassouna NA. Characterization of rhamnolipid produced by *Pseudomonas aeruginosa* isolate Bs20. *Appl Biochem Biotechnol* 2009; 157: 329-345.
27. Su HC, Ramkisson K, Doolittle J, Clark M, Khatun J, Secrest A, et al. The development of ciprofloxacin resistance in *Pseudomonas aeruginosa* involves multiple response stages and multiple proteins. *Antimicrob Agents Chemother* 2010; 54: 4626-4635.
28. O'Fallon E, Schreiber R, Kandel R, D'Agata EM. Multidrug-resistant gram-negative bacteria at a long-term care facility: assessment of residents, healthcare workers, and inanimate surfaces. *Infect Control Hosp Epidemiol* 2009; 30: 1172-1179.
29. Talebi M, Pourshafie MR, Katouli M, Mollby R. Molecular structure and transferability of Tn1546-like elements in *Enterococcus faecium* isolates from clinical, sewage, and surface water samples in Iran. *Appl Environ Microbiol* 2008; 74: 1350-1356.
30. Breidenstein EB, Khaira BK, Wiegand I, Overhage J, Hancock RE. Complex ciprofloxacin resistome revealed by screening a *Pseudomonas aeruginosa* mutant library for altered susceptibility. *Antimicrob Agents Chemother* 2008; 52: 4486-4491.
31. Schaber JA, Carty NL, McDonald NA, Graham ED, Cheluvappa R, et al. Analysis of quorum sensing-deficient clinical isolates of *Pseudomonas aeruginosa*. *J Med Microbiol* 2004; 53: 841-853.
32. Schipper C, Hornung C, Bijtenhoorn P, Quitschau M, Grond S, Streit WR. Metagenome-derived clones encoding two novel lactonase family proteins involved in biofilm inhibition in *Pseudomonas aeruginosa*. *Appl Environ Microbiol* 2009; 75: 224-233.
33. Sauer K, Camper AK, Ehrlich GD, Costerton JW, Davies DG. *Pseudomonas aeruginosa* displays multiple phenotypes during development as a biofilm. *J Bacteriol* 2002; 184: 1140-1154.
34. Shih PC, Huang CT. Effects of quorum-sensing deficiency on *Pseudomonas aeruginosa* biofilm formation and antibiotic resistance. *J Antimicrob Chemother* 2002; 49: 309-14.
35. Anderl JN, Franklin MJ, Stewart PS. Role of antibiotic penetration limitation in *Klebsiella pneumoniae* biofilm resistance to ampicillin and ciprofloxacin. *Antimicrob Agents Chemother* 2000; 44: 1818-1824.
36. Carmen JC, Nelson JL, Beckstead BL, Runyan CM, Robison RA, et al. Ultrasonic-enhanced gentamicin transport through colony biofilms of *Pseudomonas aeruginosa* and *Escherichia coli*. *J Infect Chemother* 2004; 10: 193-199.

37. Rahmati S, Yang S, Davidson AL, Zechiedrich EL. Control of the AcrAB multidrug efflux pump by quorum-sensing regulator SdiA. *Mol Microbiol* 2002; 43: 677-685.
38. Aendekerck S, Diggle SP, Song Z, Hoiby N, Cornelis P, et al. The MexGHI-OpmD multidrug efflux pump controls growth, antibiotic susceptibility and virulence in *Pseudomonas aeruginosa* via 4-quinolone-dependent cell-to-cell communication. *Microbiology* 2005; 151: 1113-1125.
39. Ahmed NA, Petersen FC, Scheie AA. AI-2 quorum sensing affects antibiotic susceptibility in *Streptococcus anginosus*. *J Antimicrob Chemother* 2007; 60: 49-53.
40. Butler MT, Wang Q, Harshey RM. Cell density and mobility protect swarming bacteria against antibiotics. *Proc Natl Acad Sci USA* 2010; 107: 3776-3781.
41. Drago L, de Vecchi E, Nicola L., Tocalli L, Gismondo MR. Effect of moxifloxacin on bacterial pathogenicity factors in comparison with amoxicillin, clarithromycin and ceftriaxone. *J Chemother* 2004; 16: 30-37.
42. Wojnicz D, Kłak M, Adamski R, Jankowski S. Influence of sub-inhibitory concentrations of amikacin and ciprofloxacin on morphology and adherence ability of uropathogenic strains. *Folia Microbiol* 2007; 52: 429-436.
43. Shepherd RW, Lindow SE. Two dissimilar N-acyl-homoserine lactone acylases of *Pseudomonas syringae* influence colony and biofilm morphology. *Appl Environ Microbiol* 2009; 75: 45-53.
44. Rasmussen TB, Bjarnsholt T, Skindersoe ME, Hentzer M, Kristoffersen P, et al. Screening for quorum-sensing Inhibitors (QSI) by use of a novel genetic system, the QSI Selector. *J Bacteriol* 2005; 187: 1799-1814.
45. Nasr S, Soudi MR, Mehrnia MR, Sarrafzadeh MH. Characterization of novel biosurfactant producing strains of *Bacillus* spp. isolated from petroleum contaminated soil. *Iran J Microbiol* 2009; 1: 54-61.
46. Tarighi S, Wei Q, Cámara M, Williams P, et al. The PA4204 gene encodes a periplasmic gluconolactonase (PpgL) which is important for fitness of *Pseudomonas aeruginosa*. *Microbiology* 2008; 154: 2979-2990.
47. Tarighi S. Characterization of the *fqsM* gene (fitness and quorum sensing modulator) in *Pseudomonas aeruginosa* and *P. syringae*. International conference on *Pseudomonas*. 2007; 08: 26.
48. Tarighi S. PA4203, a novel regulator of fitness, quorum sensing and pyoverdine systems in *Pseudomonas aeruginosa*. 13th conference of the Belgian Society for Microbiology. 2007; 11: 23.
49. Tarighi S. The *fqsM* gene is important for fitness and quorum sensing in *Pseudomonas syringae*, 59th international symposium on crop protection. 2007; 05: 22.